|
| 37067723 | CSF-based liquid biopsy pointing to a diagnosis of diffuse glioma in a patient with supposed neurodegenerative disorder. | Neurol Sci | 2023 |
| 37634617 | European Cancer Organisation Essential Requirements for Quality Cancer Care: Adult glioma. | J Cancer Policy | 2023 |
| 37289981 | The coming of age of liquid biopsy in neuro-oncology. | Brain | 2023 |
| 37140883 | Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors. | J Neurooncol | 2023 |
| 37067723 | CSF-based liquid biopsy pointing to a diagnosis of diffuse glioma in a patient with supposed neurodegenerative disorder. | Neurol Sci | 2023 |
| 37505981 | Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas. | Cell Rep | 2023 |
| 36980181 | Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation. | Cells | 2023 |
| 37634617 | European Cancer Organisation Essential Requirements for Quality Cancer Care: Adult glioma. | J Cancer Policy | 2023 |
| 37505981 | Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas. | Cell Rep | 2023 |
| 37289981 | The coming of age of liquid biopsy in neuro-oncology. | Brain | 2023 |
| 36980181 | Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation. | Cells | 2023 |
| 37140883 | Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors. | J Neurooncol | 2023 |
| 36131014 | Failure of human rhombic lip differentiation underlies medulloblastoma formation. | Nature | 2022 |
| 35511454 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. | Neuro Oncol | 2022 |
| 36000367 | Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results. | Curr Opin Oncol | 2022 |
| 36131014 | Failure of human rhombic lip differentiation underlies medulloblastoma formation. | Nature | 2022 |
| 36446943 | Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation. | Nature | 2022 |
| 35511454 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. | Neuro Oncol | 2022 |
| 36446943 | Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation. | Nature | 2022 |
| 36000367 | Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results. | Curr Opin Oncol | 2022 |
| 33140187 | High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. | Cancer Immunol Immunother | 2021 |
| 34320350 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. | Cell Rep | 2021 |
| 33547226 | Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. | Cancer Immunol Res | 2021 |
| 33140187 | High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. | Cancer Immunol Immunother | 2021 |
| 34678323 | Gamma Knife radiosurgery as primary treatment of low-grade brainstem gliomas: A systematic review and metanalysis of current evidence and predictive factors. | Crit Rev Oncol Hematol | 2021 |
| 34498344 | A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. | Oncologist | 2021 |
| 33547226 | Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. | Cancer Immunol Res | 2021 |
| 34498344 | A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. | Oncologist | 2021 |
| 34678323 | Gamma Knife radiosurgery as primary treatment of low-grade brainstem gliomas: A systematic review and metanalysis of current evidence and predictive factors. | Crit Rev Oncol Hematol | 2021 |
| 34320350 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. | Cell Rep | 2021 |
| 32285310 | Milan 2020: COVID-19, neuro-oncology and much more. | J Neurooncol | 2020 |
| 31650436 | In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. | Neurol Sci | 2020 |
| 32131407 | PGE<sub>2</sub> Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma. | Pharmaceutics | 2020 |
| 32285310 | Milan 2020: COVID-19, neuro-oncology and much more. | J Neurooncol | 2020 |
| 32575496 | Simultaneous Detection of <i>NF1</i>, <i>SPRED1</i>, <i>LZTR1</i>, and <i>NF2</i> Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. | Genes (Basel) | 2020 |
| 32678904 | Actinomycin D: a new opening for an old drug. | Neuro Oncol | 2020 |
| 31650436 | In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. | Neurol Sci | 2020 |
| 32575496 | Simultaneous Detection of <i>NF1</i>, <i>SPRED1</i>, <i>LZTR1</i>, and <i>NF2</i> Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients. | Genes (Basel) | 2020 |
| 32678904 | Actinomycin D: a new opening for an old drug. | Neuro Oncol | 2020 |
| 32131407 | PGE<sub>2</sub> Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma. | Pharmaceutics | 2020 |
| 30531922 | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Nat Med | 2019 |
| 31748746 | Longitudinal molecular trajectories of diffuse glioma in adults. | Nature | 2019 |
| 31744235 | Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma. | J Clin Med | 2019 |
| 31771235 | ABCC3 Expressed by CD56<sup>dim</sup> CD16<sup>+</sup> NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy. | Int J Mol Sci | 2019 |
| 31766501 | Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort. | Cancers (Basel) | 2019 |
| 32642658 | Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. | Neurooncol Adv | 2019 |
| 30266892 | A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. | Oncologist | 2019 |
| 30531922 | The molecular landscape of glioma in patients with Neurofibromatosis 1. | Nat Med | 2019 |
| 30418668 | Altered function of the glutamate-aspartate transporter GLAST, a potential therapeutic target in glioblastoma. | Int J Cancer | 2019 |
| 30918960 | NG2/CSPG4 in glioblastoma: about flexibility. | Neuro Oncol | 2019 |